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Abstract
Background: The aim of this study was to assess changes in metalloproteinases (MMP-2) and
tissue inhibitor of metalloproteinases (TIMP-2) following selective laser trabeculoplasty (SLT) in
patients with pseudoexfoliative glaucoma (PEXG).
Methods:  We enrolled 15 patients with PEXG and cataracts (PEXG-C group) and good
intraocular pressure (IOP) controlled with β-blockers and dorzolamide eye drops who were
treated by cataract phacoemulsification and 15 patients with pseudoexfoliative glaucoma (PEXG-
SLT group). The PEXG-SLT patients underwent a trabeculectomy for uncontrolled IOP in the eye
that showed increased IOP despite the maximum drug treatment with β-blockers and dorzolamide
eye drops and after ineffective selective laser trabeculoplasty (SLT). The control group consisted
of 15 subjects with cataracts. Aqueous humor was aspirated during surgery from patients with
PEXG-C, PEXG-SLT and from matched control patients with cataracts during cataract surgery or
trabeculectomy. The concentrations of MMP-2 and TIMP-2 in the aqueous humor were assessed
with commercially available ELISA kits.
Results: In PEXG-SLT group in the first 10 days after SLT treatment a significant reduction in IOP
was observed: 25.8 ± 1.9 vs 18.1.0 ± 1.4 mm/Hg (p < 0.001), but after a mean time of 31.5 ± 7.6
days IOP increased and returned to pretreatment levels: 25.4 ± 1.6 mm/Hg (p < 0.591). Therefore
a trabeculectomy was considered necessary.
The MMP-2 in PEXG-C was 57.77 ± 9.25 μg/ml and in PEXG-SLT was 58.52 ± 9.66 μg/ml (p <
0.066). TIMP-2 was 105.19 ± 28.53 μg/ml in PEXG-C and 105.96 ± 27.65 μg/ml in PEXG-SLT (p <
0.202). The MMP-2/TIMP-2 ratio in the normal subjects was 1.11 ± 0.44. This ratio increase to 1.88
± 0.65 in PEXG-C (p < 0.001) and to 1.87 ± 0.64 in PEXG-SLT (p < 0.001). There was no
statistically significant difference between the PEXG-C and PEXG-SLT ratios (p < 0.671).
Conclusion: This case series suggest that IOP elevation after SLT can be a serious adverse event
in some PEXG patients. The IOP increase in these cases would be correlated to the failure to
decrease the TIMP-2/MMP-2 ratio.
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Background
Argon laser trabeculoplasty has become the standard
method of treatment for medically uncontrolled open
angle glaucoma [1,2]. It has been in use since 1979 when
it was first described by Wise [3] and different types of
lasers with various wavelengths have been investigated.
The first laser used was an argon laser, but recently a Q
switched frequency doubled Nd:YAG laser was proposed
for use in trabeculoplasty [4,5], described as selective laser
trabeculoplasty (SLT).
A number of theories have been proposed to explain the
effect of argon laser trabeculoplasty (ALT) and SLT on
aqueous outflow. The mechanical theory suggests that
ALT causes photocoagulative damage to the trabecular
meshwork (TM), which results in collagen shrinkage and
subsequent scarring of the TM [6]. The cellular theory is
based on the migration of macrophages, due to coagulat-
ive necrosis induced by laser burns, which phagocytose
debris and clear the TM [6]. SLT selectively targets pig-
mented TM cells, while it spares collateral cells and tissue
from thermal damage and can maintain the architecture
of the TM [7]. Experiments have shown that there is also a
third mechanism involved in laser trabeculoplasty which
causes an increase in the production of metalloprotein-
ases (MMPs) induced by the TM photocoagulation [8,9].
These enzymes are responsible for the extracellular matrix
(ECM) turnover. Their action is countered by a family of
tissue inhibitors, the tissue inhibitors of metalloprotein-
ases (TIMPs).
The aim of this study was to assess changes in the MMP-2
and TIMP-2 values in a group of patients with pseudoex-
foliative syndrome glaucoma (PEXG) in whom SLT failed
to decrease intraocular pressure (IOP).
Methods
We assess the MMP-2 and TIMP-2 values in the aqueous
samples of 15 patients with pseudoexfoliative glaucoma
(PEXG-SLT group) (8 males and 7 females aged from 58
to 66, mean 63.8 yrs) that presented post-SLT IOP eleva-
tions. As control groups we enrolled 15 patients with
pseudoexfoliative glaucoma and cataracts (PEXG-C
group) (9 females and 6 males, aged from 61 to 68, mean
65.4 yrs) and 15 subjects with cataracts (4 males and 11
females aged between 62 and 74 years, mean 68.3 yrs), All
patients were recruited from the Glaucoma Disease Serv-
ice and from the Ophthalmology Services of the S. Orsola-
Malpighi Hospital, Bologna.
Patients with other ocular or systemic disorders, such as
inflammatory diseases or diabetes mellitus, were excluded
from the study.
The study was approved by the institutional ethic commit-
tee of the S. Orsola-Malpighi hospital (ref: 2007-007744-
98). Before enrolment, patients were informed of the pro-
cedures and the aim of the study following which they
signed a written consent form.
After a complete ocular examination, including assess-
ment of visual acuity, anterior segment biomicroscopy,
applanation tonometry and visual field evaluation (Hum-
phrey 30.2 full threshold programme), the PEXG-C
patients who had good intraocular pressure (IOP) control
with β-blockers and dorzolamide eye drops underwent
cataract phacoemulsification. The PEXG-SLT patients
underwent a trabeculectomy for uncontrolled IOP in the
eye that showed increased IOP, despite being under max-
imum drug treatment with β-blockers and dorzolamide
eye drops and after having received selective laser trabecu-
loplasty (SLT).
SLT was performed with a Selecta 7000 (Q switched, fre-
quency doubled, 532 Nd:YAG laser) using 50 non-over-
lapping applications in the inferior 180° of the trabecular
meshwork, with a spot size of 400 μm and pulse duration
of 3 ns. The initial energy used was 0.8 mJ. The energy was
increased or decreased until bubble formation and then
was decreased by 0.1 mJ for the remainder of the treat-
ment.
The laser treatment was considered to be effective when a
decrease of 20% in the IOP was obtained as compared to
the base values or when the visual field was stabilized.
In the first 10 days after SLT treatment a significant reduc-
tion in IOP was observed: 25.8 ± 1.9 vs 18.1.0 ± 1.4 mm/
Hg (p < 0.001), but after a mean time of 31.5 ± 7.6 days
IOP increased and returned to pretreatment levels: 25.4 ±
1.6 mm/Hg (p < 0.591). Therefore a trabeculectomy was
considered necessary.
Before enrolment, all patients were informed of the proce-
dures and the aim of the study and they signed a written
consent form.
Aqueous humor was aspirated during surgery from
patients with PEXG-C, PEXG-SLT and from matched con-
trol patients with cataracts. Thus 80–100 μl of aqueous
humor was aspirated through an ab externo limbal para-
centesis site using a tuberculin syringe with a 30-gauge
needle. Meticulous care was taken to avoid touching
intraocular tissues and to prevent contamination of the
aqueous samples with blood. The samples were immedi-
ately frozen in liquid nitrogen and stored at -80°C.
The concentrations of MMP-2 and TIMP-2 in aqueous
humor were assessed by ELISA using commercially availa-BMC Ophthalmology 2008, 8:20 http://www.biomedcentral.com/1471-2415/8/20
Page 3 of 5
(page number not for citation purposes)
ble enzyme immunoassay kits (Biotrak; Amersham Bio-
sciences, Piscataway, NJ) according to the manufacturer's
instructions.
Differences in MMP-2 and TIMP-2 levels between groups,
as measured by ELISA in aqueous humor samples, were
statistically evaluated using the Wilcoxon signed rank test
and a p < 0.05 was considered significant. Data are pre-
sented as means ± standard deviation (SD). The analysis
was performed using SSI (version 11, Systat Software Inc.,
San Jose, California, USA) for Macintosh.
Results
There was a significant difference between controls and
PEXG-C in terms of MMP-2 (p < 0.013) and TIMP-2 (p <
0.005) values. The same statistical significance was found
in PEXG-SLT both for MMP-2 (p < 0.013) and TIMP-2 (p
< 0.005).
The TIMP-2/MMP-2 ratio in controls was 1.11 ± 0.44. This
ratio increased to 1.88 ± 0.65 in PEXG-C (p < 0.001) and
to 1.87 ± 0.64 in PEXG-SLT (p < 0.001).
The PEXG-C and PEXG-SLT ratios were not significantly
different (p < 0.671).
The results are summarised in Tables 1 and 2.
Discussion
Our study shows that the TIMP-2/MMP-2 ratio is higher
in patients with PEXG-C and PEXG-SLT than in the cata-
ract control group.
After the initial success of selective laser trabeculoplasty
treatment with a reduction in IOP of 20% compared with
the baseline values, eyes with PEXG-SLT showed a pro-
gressive increase in IOP, which, after a mean of one
month returned to similar values to those presented
before treatment. The TIMP-2/MMP-2 ratio in the PEXG-
SLT patients did not differ significantly from that in PEXG-
C patients (p < 0.671).
SLT has been shown to be effective in long- and short-
term treatment of POAG and is comparable to ALT [5,9]
but some studies have reported post-operative IOP
increase as a complication of SLT [5,9-11]. The mean inci-
dence of increased IOP after SLT is 2.4% but no author has
specified whether eyes in which SLT had failed had special
trabecular meshwork features. Only Harasymowycz et al.
reported the complication of IOP elevations after SLT in
patients with a heavily pigmented trabecular meshwork
[11] that required surgical trabeculectomy. They suggested
that increased IOP may be related to trabeculitis or
increased angle scarring [11].
The active mechanism of selective laser trabeculoplasty is
still the subject of debate, although it has been suggested
that besides the action focused on the pigmented cells of
the trabecular meshwork [4] there is also an enzymatic
action that stimulates the production of metalloprotein-
ases [8,9], as already demonstrated experimentally with
other types of laser [13].
Metalloproteinases (MMPs) are a very numerous and het-
erogeneous family of zinc-dependent proteinases that ful-
fil the role of degrading the ECM components to maintain
homeostasis [14,15]. The various enzymes are distin-
guished on the basis of the type of media that they
degrade: collagenases, gelatinases, stromelinases and the
membrane-type MMPs [17-19].
MMPs are secreted in the form of zymogens (pro-
enzymes) that are activated by a selective proteolysis by
part of a serine proteinase. Once activated, MMPs begin
their proteolytic action on the ECM [17-19]. To guarantee
the balance between ECM degradation and deposition
there are tissue inhibitors of metalloproteinases (TIMPs)
that block them [13,15,18,19].
MMP-2 is the major metalloproteinase secreted after laser
therapy and is inhibited by TIMP-2 [8,20,21]. In pseu-
doexfoliative glaucoma (PEXG), the enzyme balance
between MMP-2 and TIMP-2, already impaired by the
pseudoexfoliative syndrome (PEX), is seriously altered
even compared with POAG [22,23].
PEX is a degenerative fibrillopathy characterised by the
production and accumulation of extracellular fibrillar
material, not just in the anterior segment of the eye [24],
but also in numerous extraocular tissues [25,26]. At an
ocular level, there is atrophy of the iris dilator muscle fiber
cells [27,28], degeneration of the irideal pigment with dis-
Table 1: Levels of MMP-2 and TIMP-2 in PEXG with cataract, PEXG after SLT and Cataract groups.
Cataract PEXG-C p < 0.05 PEXG-SLT p < 0.05
MMP-2 ng/mL 55.04 ± 10.24 57.77 ± 9.25 0.013 58.52 ± 9.66 0.013
TIMP-2 ng/mL 54.43 ± 8.18 105.19 ± 28.53 0.005 105.96 ± 27.65 0.005
TIMP-2/MMP-2 1.11 ± 0.44 1.88 ± 0.65 0.001 1.87 ± 0.64 0.001
Levels of MMP-2 and TIMP-2 in aqueous humor and TIMP-2/MMP-2 ratio of patients with PEXG and cataract (PEXG-C), PEXG after selective laser 
trabeculoplasty (PEXG-SLT) and in healthy patients with cataract.BMC Ophthalmology 2008, 8:20 http://www.biomedcentral.com/1471-2415/8/20
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persion of melanin, peripupillar atrophy and an increase
in the trabecular meshwork pigmentation [29-31]. Fur-
thermore, at the iris level there is also a general vasculop-
athy with deposits of pseudoexfoliative material that lead
to a thinning of the basal membrane and degeneration of
the adventitial cells [32,33], which explains the hypoper-
fusion and neovascularization of the iris [34,35].
As for the trabecular meshwork, a typical feature is the
excessive accumulation of the extracellular matrix mate-
rial in the juxtacanalicular tissue [36]. This accumulation
explains the increased resistance to aqueous outflow
found in eyes with PEX [37,38]. The deposits that are
found in the iris vessels and the trabecular meshwork in
PEX consist of numerous substances, including laminin,
fibronectin, alpha-elastin, tropoelastin, fibrillin and P-
amyloid protein [24].
P-amyloid protein plays an important role in the altera-
tion of ECM homeostasis since it can increase MMP pro-
duction and activity [39].
In our study levels of MMP-2, the predominant gelatinase
in aqueous humor, and TIMP-2 in PEXG and controls
were in line with previous findings [22,23].
Our results suggest that in this case series of PEXG, a par-
ticular type of glaucoma in which there is upregulation of
MMP-2 production with a marked increase in the relative
inhibitors [22,23], the changes in the TIMP-2/MMP-2
ratio that can be obtained with laser trabeculoplasty are
insignificant and thus are unable to decrease intraocular
pressure.
Conclusion
In conclusion, we can be said that in some cases of PEXG
may be a significant risk of IOP elevation after SLT. The
IOP increase in these cases would be correlated to the fail-
ure to decrease the TIMP-2/MMP-2 ratio.
Further studies are needed for evaluation of this phenom-
enon and determination for incidence.
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